Liposomal simvastatin attenuates neointimal hyperplasia in rats

AAPS Journal

Volumn 12, Issue 2, 2010, Pages 181-187

  Afergan, Eyal ^a   David, Meital Ben ^a   Epstein, Hila ^a   Koroukhov, Nickolay ^a   Gilhar, Dalia ^a   Rohekar, Keren ^a   Danenberg, Haim D ^b   Golomb, Gershon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Drug delivery systems; Liposomes; Monocytes; Restenosis; Statins

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALENDRONIC ACID; LIPOSOME; SIMVASTATIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; ATTENUATION; BALLOON OCCLUSION; BLOOD ANALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; MACROPHAGE; MALE; MONOCYTE; MORPHOMETRICS; NONHUMAN; RAT; RESTENOSIS; SINGLE DRUG DOSE;

ANIMALS; BALLOON DILATATION; CAROTID ARTERY INJURIES; CELL PROLIFERATION; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; GRAFT OCCLUSION, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERPLASIA; LIPOSOMES; MALE; MONOCYTES; RATS; SIMVASTATIN;

EID: 77950685982     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9173-5     Document Type: Article

References (62)

1. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J. 2004;25(19):1679-1687 (Pubitemid 39286632)
2. Dobesh PP, Stacy ZA, Ansara AJ, Enders JM. Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease. Pharmacotherapy. 2004;24(11):1554-1577 (Pubitemid 39426352)
3. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol. 2005;95(12):1469-1472
4. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119(12):1056-1061 (Pubitemid 44826931)
5. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202. (Pubitemid 43929240)
6. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519-1521 (Pubitemid 39410418)
7. Nilsen DW, Melberg T, Larsen AI, Barvik S, Bonarjee V. Late complications following the deployment of drug-eluting stents. Int J Cardiol. 2006;109(3):398-401.
8. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA. 1998;95(17):10134-10139 (Pubitemid 28415307)
9. Bayes-Genis A, Campbell JH, Carlson PJ, Holmes Jr DR, Schwartz RS. Macrophages, myofibroblasts and neointimal hyperplasia after coronary artery injury and repair. Atherosclerosis. 2002;163(1):89-98. (Pubitemid 34615729)
10. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation. 1992;86(6 Suppl):III47-52.
11. Welt FG, Tso C, Edelman ER, Kjelsberg MA, Paolini JF, Seifert P, et al. Leukocyte recruitment and expression of chemokines following different forms of vascular injury. Vasc Med. 2003;8 (1):1-7. (Pubitemid 36781066)
12. Cohen-Sela E, Dangoor D, Epstein H, Danenberg HD, Golomb G, Gao J. Nanospheres of bisphosphonates attenuate intimal hyperplasia. J Nanosci Nanotech. 2006;6:3226-3234 (Pubitemid 44580005)
13. Cohen-Sela E, Rosenzweig O, Gao J, Epstein H, Gati I, Reich R, et al. Alendronate- loaded nanoparticles deplete monocytes and attenuate restenosis. J Controlled Rel. 2006;113(1):23-30. (Pubitemid 43818160)
14. Danenberg HD, Fishbein I, Epstein H, Waltenberger J, Moerman E, Monkkonen J, et al. Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon injury in the rat carotid artery. J Cardiovasc Pharmacol. 2003;42(5):671-679 (Pubitemid 37305987)
15. Danenberg HD, Fishbein I, Gao J, Monkkonen J, Reich R, Gati I, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation. 2002;106(5):599-605. (Pubitemid 34827711)
16. Danenberg HD, Golomb G, Groothuis A, Gao J, Epstein H, Swaminathan RV, et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation. 2003;108(22):2798-2804 (Pubitemid 37498983)
17. Doggrell SA. Statins in the 21st century: end of the simple story? Expert Opin Investig Drugs. 2001;10(9):1755-1766 (Pubitemid 32827434)
18. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002;86(1):5-18.
19. Horlitz M, Sigwart U, Niebauer J. Fighting restenosis after coronary angioplasty: contemporary and future treatment options. Int J Cardiol. 2002;83(3):199-205. (Pubitemid 34564500)
20. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000;35(1):214-221 (Pubitemid 30061283)
21. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105(25):3017-3024 (Pubitemid 34693836)
22. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203(2):325-330
23. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285 (4):430-436 (Pubitemid 32097261)
24. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol. 2000;85(8):962-968 (Pubitemid 30176134)
25. Bunch TJ, Muhlestein JB, Anderson JL, Horne BD, Bair TL, Jackson JD, et al. Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. Am J Cardiol. 2002;90(3):299-302.
26. Horlitz M, Sigwart U, Niebauer J. Statins do not prevent restenosis after coronary angioplasty: where to go from here? Herz. 2001;26(2):119-128 (Pubitemid 32335774)
27. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDAACS randomized trial. J Am Coll Cardiol. 2007;49(12):1272-1278 (Pubitemid 46467240)
28. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King 3rd SB, Ivanhoe R, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med. 1994;331(20):1331-1337 (Pubitemid 24347002)
29. Mulder HJ, Bal ET, Jukema JW, Zwinderman AH, Schalij MJ, van Boven AJ, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol. 2000;86(7):742-746
30. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nature reviews. 2006;6(5):358-370
31. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen- containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581-589
32. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6 (12):1399-1402 (Pubitemid 32001026)
33. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977-987
34. Fildes JE, Shaw SM, Mitsidou A, Rogacev K, Leonard CT, Williams SG, et al. HMG- CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation. Transpl Immunol. 2008;19(2):152-157
35. Kim YC, Song SB, Lee MH, Kang KI, Lee H, Paik SG, et al. Simvastatin induces caspase-independent apoptosis in LPSactivated RAW264.7 macrophage cells. Biochem Biophys Res Commun. 2006;339(3):1007-1014 (Pubitemid 41772912)
36. Raz A, Bucana C, Fogler WE, Poste G, Fidler IJ. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res. 1981;41 (2):487-494 (Pubitemid 11179386)
37. Monkkonen J, Valjakka R, Hakasalo M, Urtti A. The effects of liposome surface charge and size on the intracellular delivery of clodronate and gallium in vitro. Int J Pharm. 1994;107:189-197 (Pubitemid 24182103)
38. van Etten EW, ten Kate MT, Snijders SV, Bakker-Woudenberg IA. Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system. Antimicrob Agents Chemother. 1998;42(7):1677-1681 (Pubitemid 28311561)
39. Patel HM, Moghimi SM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-the concept of tissue specificity. Adv Drug Deliv Rev. 1998;32 (1-2):45-60.
40. Moghimi SM, Hunter AC. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm Res. 2001;18(1):1-8.
41. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463-478 (Pubitemid 37237636)
42. Epstein H, Gutman D, Cohen-Sela E, Haber E, Elmalak O, Koroukhov N, et al. Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization. AAPS J. 2008;10(4):505-515
43. Afergan E, Epstein H, Koroukhov N, Klein M, Litchi A, Mishani E, et al. Biodistribution and imaging studies of 67 Ga-labeled liposomes in rabbits with a vascular injury. J Drug Deliv Sci Technol. 2009;19(4):263-268
44. Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD, et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release. 2008;132(2):84-90.
45. van Rooijen N, van Kesteren-Hendrikx E. "In vivo" depletion of macrophages by liposome-mediated suicide. Methods Enzymol. 2003;373:3-16.
46. Epstein H, Berger V, Levi I, Eisenberg G, Koroukhov N, Gao J, et al. Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J Controlled Rel. 2007;117(3):322-332 (Pubitemid 46216576)
47. Hegyesi H, Csaba G. Time- and concentration-dependence of the growth-promoting activity of insulin and histamine in Tetrahymena. Application of the MTT method for the determination of cell proliferation in a protozoan model. Cell Biol Int. 1997;21(5):289-293 (Pubitemid 27355090)
48. Golomb G, Fishbein I, Banai S, Mishaly D, Moscovitz D, Gertz SD, et al. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis. 1996;125(2):171-182 (Pubitemid 26249207)
49. Fishbein I, Waltenberger J, Banai S, Rabinovich L, Chorny M, Levitzki A, et al. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol. 2000;20(3):667-676 (Pubitemid 30151679)
50. Schroit AJ, Madsen J, Nayar R. Liposome cell interactions: in vitro discrimination of uptake mechanism and in vivo targeting strategies to mononuclear phagocytes. Chem Phys Lipids. 1986;40(2-4):373-393 (Pubitemid 16040788)
51. Patel HM. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst. 1992;9 (1):39-90.
52. Rodrigueza WV, Pritchard PH, Hope MJ. The influence of size and composition on the cholesterol-mobilizing properties of liposomes in vivo. Biochim Biophys Acta. 1993;1153(1):9-19.
53. Kao YJ, Juliano RL. Interactions of liposomes with the reticuloendothelial system. Effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. Biochim Biophys Acta. 1981;677(3-4):453-461
54. Sato Y, Kiwada H, Kato Y. Effects of dose and vesicle size on the pharmacokinetics of liposomes. Chem Pharm Bull (Tokyo). 1986;34(10):4244-4252 (Pubitemid 17201158)
55. Hanke H, Hassenstein S, Ulmer A, Kamenz J, Oberhoff M, Haase KK, et al. Accumulation of macrophages in the arterial vessel wall following experimental balloon angioplasty. Eur Heart J. 1994;15(5):691-698 (Pubitemid 24186339)
56. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation. 2001;104 (18):2228-2235 (Pubitemid 33043305)
57. Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol. 2004;43 (1):18-23. (Pubitemid 38045908)
58. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994;90(2):775-778 (Pubitemid 24242744)
59. Haber E, Danenberg HD, Koroukhov N, Ron-El R, Golomb G, Schachter M. Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model. Hum Reprod. 2009;24(2):398-407.
60. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323 (Pubitemid 37186209)
61. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer- based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221-31. (Pubitemid 38067635)
62. Web site: http://clinicaltrials.gov/ct2/show/NCT00739466.